Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 3/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716485 | 0.86 | HSD17B10 (0.50) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL502532 | 0.86 | HSD17B10 (0.50) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL11789449 | 0.84 | TSHR (0.48) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL11357081 | 0.83 | HSD17B10 (0.46) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL20666764 | 0.83 | HSD17B10 (0.46) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL1493888 | 0.82 | PTGS1 (0.59) | ALDH1A1ALOX12HTTHIF1AGAA | |
| SCHEMBL1596005 | 0.81 | HSD17B10 (0.54) | ALDH1A1ALOX12HIF1ATYRTSHR | |
| SCHEMBL29465800 | 0.81 | HSD17B10 (0.54) | ALDH1A1ALOX12HIF1ATYRTSHR | |
| SCHEMBL4458922 | 0.81 | HSD17B10 (0.54) | ALDH1A1ALOX12HIF1ATYRTSHR | |
| SCHEMBL30343463 | 0.81 | HSD17B10 (0.54) | ALDH1A1ALOX12HIF1ATYRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-3954889-A | Process for the production of 1,1,3,3-substituted hydroxyindanes | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | claimed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-112679635-B | Preparation method of supported metallocene catalyst and catalyst prepared by preparation method | 中国石油化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| WO-2023150601-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-100378165-C | Epoxy resin composition for encapsulating optical semiconductor | CHANGCHUN ARTIFICIAL RESIN FAC (CN) | 2008-04-02 | — | — | CN | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006012504-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | DAIAMED, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| CN-1613910-A | Epoxy resin composition for encapsulating optical semiconductor | CHANGCHUN ARTIFICIAL RESIN FAC (CN) | 2005-05-11 | — | — | CN | disclosed |
| US-20040254305-A1 | Epoxy resin composition for photosemiconductor package | CHANG CHUN PLASTIC CO., LTD. (TW) | 2004-12-16 | — | — | US | disclosed |
| US-4370505-A | 1,1,3,3-Substituted hydroxyindanes | BAYER AKTIENGESELLSCHAFT (DE) | 1983-01-25 | — | — | US | disclosed |
| US-3983292-A | Pressure sensitive recording papers | SANKO CHEMICAL COMPANY LTD. (JA) | 1976-09-28 | — | — | US | disclosed |
| US-3954889-A | Process for the production of 1,1,3,3-substituted hydroxyindanes | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | ALDH1A1 473/4885ALOX12 297/4885HTT 4871/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | ALDH1A1 473/4885ALOX12 297/4885HTT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.